Skip to main content
ENGN
NASDAQ Life Sciences

enGene's LEGEND Cohort 1 CR Rises to 56%, BLA Filing Set for Q4 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.89
Mkt Cap
$120.629M
52W Low
$1.4
52W High
$12.25
52W Position info
35% above low
Off High info
85% below high
Rel. Volume info
3.4× avg
Market data snapshot near publication time

ENGN sits 35% above its 52-week low of $1.4 on elevated volume (3.4× avg).

Summary

enGene reported improved pivotal LEGEND Cohort 1 data for detalimogene — 56% complete response at any time and 43% estimated 12-month durability — and said FDA alignment clears it to start a BLA submission by year-end 2026, with about $245.8M of cash to fund it.


Key Events · Product Development and Regulatory · ENGN

  • Pivotal CR Rate Improves to 56%

    Complete response at any time rose to 56% (CI: 47%, 65%) in 120 efficacy-evaluable patients versus 54% in the April 2026 analysis.

  • Durability and 12-Month CR Jump

    Kaplan-Meier estimate of duration of response ≥12 months improved to 43% from 25%, median duration to 10.1 months from 8.6 months, and landmark 12-month CR to 24% from 13%.

  • FDA Aligns on Evaluable Population

    A positive pre-BLA meeting produced alignment on the efficacy-evaluable population (125 trial patients less 5 exclusions = 120), clearing a key submission question.

  • BLA Filing Targeted for Q4 2026

    enGene expects to initiate the BLA submission by year-end 2026, complete it in the first half of 2027, with potential FDA approval in 2027; surfactant cohort data expected mid-2027.


Analysis · ENGN · Life Sciences

This is the dataset enGene intends to file for approval, and every efficacy measure improved versus the April 2026 cut: CR at any time 56% vs 54%, 12-month landmark CR 24% vs 13%, and the Kaplan-Meier estimate of durability past 12 months 43% vs 25%. Just as important, the pre-BLA meeting with the FDA settled the efficacy-evaluable population (120 of 125 patients), removing a key ambiguity before submission. With roughly $245.8M of cash at October 31, the company says it is funded through the BLA filing and potential 2027 approval, so this is a clinical and regulatory de-risking event rather than a financing one. The remaining swing factor is durability, where nine patients are still pending their 12-month assessment.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENGN was trading at $1.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $120.6M. The 52-week trading range was $1.40 to $12.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENGN - Latest Insights

ENGN
Nov 12, 2026, 1:39 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $1.82
Real-time Price: $1.88 info
Change: +$0.060 (+3%) info
Market Cap: $120.629M info
ENGN
Sep 08, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.81
Real-time Price: $1.88 info
Change: +$0.070 (+4%) info
Market Cap: $120.629M info
ENGN
Sep 08, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $1.81
Real-time Price: $1.88 info
Change: +$0.070 (+4%) info
Market Cap: $120.629M info
ENGN
Jul 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.82
Real-time Price: $1.88 info
Change: +$0.060 (+3%) info
Market Cap: $120.629M info
ENGN
Jun 18, 2026, 4:06 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $1.72
Real-time Price: $1.88 info
Change: +$0.160 (+9%) info
Market Cap: $120.629M info